Novistig (Glycopyrronium Bromide, Neostigmine Methylsulfate)

Glycopyrronium bromide is a competitive antagonist of muscarinic acetylcholine receptors. By blocking these receptors, it suppresses parasympathetic activity, leading to decreased secretions from salivary, bronchial, and gastrointestinal glands and reduced smooth‑muscle tone, which facilitates airway management during surgery.

The appropriate dose of Novistig is determined by the prescribing clinician based on the specific clinical scenario, patient weight, renal function, and the desired effect. Healthcare professionals adjust the volume and rate of intravenous administration to achieve optimal secretions control or neuromuscular blockade reversal.

Safety data for Novistig in pregnancy and lactation are limited. It should be used only if the potential therapeutic benefit justifies any possible risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the Novistig product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Novistig combines two mechanisms in a single formulation, offering both anticholinergic secretions control (similar to glycopyrrolate) and rapid neuromuscular blockade reversal (like neostigmine alone). This dual action can simplify inventory and reduce preparation time compared with using separate agents, while maintaining comparable efficacy and safety profiles.

Novistig must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Before use, inspect for particulate matter or discoloration and discard if any abnormalities are observed.

Novistig is administered intravenously. The solution can be given undiluted or diluted in compatible IV fluids, depending on the clinical protocol. Injection should be performed slowly, typically over 1–2 minutes for secretions control, or as directed for neuromuscular blockade reversal, with continuous monitoring of vital signs.

Serious adverse events include severe bradycardia or arrhythmias, bronchospasm, anaphylactic reactions, and cholinergic crisis leading to muscle weakness and respiratory compromise. Prompt recognition and immediate medical intervention are essential if any of these reactions occur during or after administration.

Novistig is contraindicated in patients with known hypersensitivity to glycopyrronium bromide, neostigmine methylsulfate, or any excipients in the formulation. It should also be avoided in individuals with uncontrolled severe asthma, recent myocardial infarction, or those taking other potent anticholinergic drugs without careful supervision.